Phase I – First Administration to Humans

783 trials 323 recruiting

Filter these 783 trials by condition, country, sponsor and more.

Open in Search →

A Study to Evaluate the Safety and Tolerability of ARV-806 in Adults with Advanced Cancer that has the KRAS G12D Mutation Pending

2025-521062-10-00 KRAS G12D Mutated Advanced Solid Tumors
First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors Pending

2025-521173-13-00 Advanced Solid Tumors
A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced… Pending

2025-521438-27-00 advanced, unresectable and/or metastatic solid tumors
A study testing a new treatment called TK-6302 for the first time in people with advanced cancers that have a genetic marker called HLA-A02:… Pending

2025-521603-46-00 Advanced PRAME Positive Solid Tumors
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants Pending

2025-521758-40-00 Geographic Atrophy
A Study Testing the Investigational Drug XmAb541 in people with Advanced Cancer Pending

2025-521981-90-00 Advanced Solid Tumors
A study in people with advanced cancer (solid tumours) to test different doses of BI 3810944 and to find out whether it helps Pending

2025-522045-21-00 Melanoma
A PHASE 1/1B, OPEN-LABEL, MULTICENTER, FIRST-IN-HUMAN DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC… Pending

2025-522148-42-00 Advanced Solid Tumours
A Phase 1, placebo-controlled, randomized, participant- and assessor-blind, single-center study to assess the safety and immunogenicity of 2… Pending

2025-522293-37-00 Nipah Virus
A Study of LY4257496 in Participants With Cancer (OMNIRAY) Pending

2025-522367-15-00 Breast Neoplasms Colorectal Neoplasms Prostate Neoplasm
A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma Pending

2025-522523-96-00 T-cell Non-Hodgkin Lymphoma
A Phase 1, Randomized, Placebo-controlled Study with a Double-blind Period with Open-label Extension Period to Evaluate the Safety, Tolerabi… Pending

2025-522582-30-00 Alzheimer’s Disease
Phase 1b Study of VERVE-201 in Patients with Refractory Hyperlipidemia Pending

2025-522617-39-00 Refractory hyperlipidemia
A Phase I, Open-label, Randomized, Active-Controlled, to Evaluate the Safety and Immunogenicity of the DuoChol Oral Cholera Vaccine in 18 to… Pending

2025-522633-57-00 Prevention of Cholera disease
BBT001 in Healthy Volunteers and in Adult Patients with Atopic Dermatitis Pending

2025-522918-23-00 Atopic Dermatitis
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy … Pending

2025-523142-28-00 Chronic Obstructive Pulmonary Disease (COPD) Chronic Rh
A phase 1, open-label, dose-escalation and dose-expansion study evaluating the safety, feasability and efficacy of ODI-2001 vaccine, a perso… Pending

2025-523172-23-00 Metastatic or locally advanced pancreatic cancer
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors Pending

2025-523232-39-00 Advanced Solid Tumors
A study to find how safe different doses of LFD-200 are and how it works in both healthy people and people with moderate to severe rheumato… Pending

2025-523409-13-00 Moderate to Severe Rheumatoid Arthritis
A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a single dose of REGN22044 in Healthy Adults Pending

2025-523562-24-00 Heathy volunteer trial
A Study of GEN1106 in Participants with Solid Tumors Pending

2025-523760-21-00 Metastatic or advanced malignant solid tumors
A study to test single and multiple doses of MER511 given to adults with Graves’ disease Pending

2025-523823-23-00 Graves’ disease
AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors… Pending

2025-524056-63-00 microsatellite instability high/mismatch repair deficie
First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participa… Pending

2025-524165-25-00 Neoplasms